Back to Insulin research
insulin glp 1 agonist rct 2021-01-18 ClinicalTrials

Simplifying Type 2 Diabetes Management with Once-Weekly Semaglutide and Basal Insulin

Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D

Study Design

Population
The study population is not specified in the provided digest.
Intervention
Once-weekly semaglutide was administered.
Comparator
The comparator is not specified in the provided digest.
Outcome
The primary outcome measured is not specified in the provided digest.

Abstract

Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With Type-2 Diabetes Mellitus (TRANSITION-T2D) A Prospective Randomized Controlled Trial NCT ID: NCT04538352 Status: COMPLETED Sponsor: The C…

insulin semaglutide glp 1 agonist protocol relevant
Source: clinicaltrials:NCT04538352 · Ingested 2026-04-24 · Digest: gemini-2.5-flash